Magis Pharma
0500.721.819 · rovalta.com · 25/09/2026
NORMAL SITUATION
Magis Pharma
Company — Normal situation.
Financial year 2024 · Closed on 26/07/2024
Net result448,9 k €+407,5 %over 1 year
Gross margin578,4 k €
Equity1,9 M €+31,3 %over 1 year
Workforce0,0 ETP-100,0 %over 1 year
Overview
Identity
Source · BCE/KBOMagis Pharma is a company registered in Belgium.
- Legal situation
- Normal situation
- BCE/KBO no. / VAT
- BE 0500.721.819
- Legal form
- Private limited company
- Contributed capital
- 2 095 104,96 €
- Latest accounts
- 26/07/2024
- Average workforce
- 0,0 ETP
Joint committees (3)
- 116
- 207
- 218
Signals
ProfitableSolid equityGood liquidityPositive cashflowPositive EBITDAHealthy social debts
Financials
Source · NBB, 12 filingsTrend over 12 financial years
| 2024 | 2023 | 2022 | 2021 | 2020 | |||||
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Gross margin | 578,4 k € | – | – | – | 1,3 M € | ||||
| EBITDA | 500,9 k € | +924% | 48,9 k € | +83.0% | 26,7 k € | -89.3% | 250,7 k € | -43.3% | 442,1 k € |
| Operating result | 500,9 k € | +632% | -94,2 k € | -2.3% | -92 k € | -163% | 146,8 k € | -59.4% | 361,3 k € |
| Net result | 448,9 k € | +407% | -146 k € | -4.4% | -139,8 k € | -282% | 76,7 k € | -75.6% | 313,9 k € |
| Balance sheet | |||||||||
| Equity | 1,9 M € | +31.3% | 1,4 M € | -9.2% | 1,6 M € | -8.1% | 1,7 M € | +4.7% | 1,6 M € |
| Total assets | 5,3 M € | -12.6% | 6,1 M € | +63.2% | 3,7 M € | -1.5% | 3,8 M € | +6.5% | 3,6 M € |
| Cash | 4,7 k € | -97.9% | 225,6 k € | +239% | 66,5 k € | -49.0% | 130,4 k € | -67.8% | 405,3 k € |
| Debts | 3,5 M € | -26.1% | 4,7 M € | +117% | 2,2 M € | +3.8% | 2,1 M € | +8.7% | 1,9 M € |
| Other | |||||||||
| Workforce | 0,0 ETP | -100% | 17,8 ETP | +13.4% | 15,7 ETP | +2.6% | 15,3 ETP | 0.0% | 15,3 ETP |
Board of directors
Source · NBB, accounts to 26/07/20243 active · 41 ended
Active mandates
Ended mandates
Financials
Full financial information
Source · NBB| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Type of account | Abridged model | Full model | Full model | Full model | Abridged model | Abridged model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2019 |
| Closing of the financial year | 26/07/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Length of the financial year | 7 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 21/02/2025 | 26/06/2024 | 03/08/2023 | 29/06/2022 | 11/08/2021 | 09/07/2020 |
| General meeting | 26/07/2024 | 30/05/2024 | 07/07/2023 | 11/05/2022 | 12/05/2021 | 10/06/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Source · NBBLooking for more information about this company?
Try for 7 daysAnnual accounts filings
Source · NBB, 12 filings| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Abridged model | 26/07/2024 | 26/07/2024 | 21/02/2025 | Dutch | |
| Full model | 31/12/2023 | 30/05/2024 | 26/06/2024 | Dutch | |
| Full model | 31/12/2022 | 07/07/2023 | 03/08/2023 | Dutch | |
| Full model | 31/12/2021 | 11/05/2022 | 29/06/2022 | Dutch | |
| Abridged model | 31/12/2020 | 12/05/2021 | 11/08/2021 | Dutch | |
| Abridged model | 31/12/2019 | 10/06/2020 | 09/07/2020 | Dutch | |
| Abridged model | 31/12/2018 | 08/05/2019 | 21/08/2019 | Dutch | |
| Abridged model | 31/12/2017 | 09/05/2018 | 21/06/2018 | Dutch | |
| Abridged model | 31/12/2016 | 10/05/2017 | 18/09/2017 | Dutch | |
| Abridged model | 31/12/2015 | 11/05/2016 | 25/06/2016 | Dutch | |
| Abridged model | 31/12/2014 | 27/05/2015 | 15/07/2015 | Dutch | |
| Abridged model | 31/12/2013 | 22/07/2014 | 07/08/2014 | Dutch |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Disclaimer
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Source · NBB, accounts to 26/07/20243 active · 41 ended
Active mandates
Ended mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Belgian Official Gazette publications
Source · Belgian Official Gazette- Mandates26/09/2024ONTSLAGEN - BENOEMINGEN
- Mandates27/03/2023ONTSLAGEN - BENOEMINGEN
- Mandates29/04/2021ONTSLAGEN - BENOEMINGEN
- Registered office16/04/2021STATUTEN (VERTALING, COÖRDINATIE, OVERIGE WIJZIGINGEN, ) - DIVERSEN - MAATSCHAPPELIJKE ZETEL
- Restructuring07/02/2020BENAMING - DOEL - KAPITAAL - AANDELEN - WIJZIGING RECHTSVORM - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
- Restructuring20/11/2019ONTSLAGEN - BENOEMINGEN - RUBRIEK HERSTRUCTURERING (FUSIE, SPLITSING, OVERDRACHT VERMOGEN, ENZ...)
- Mandates20/11/2019ONTSLAGEN - BENOEMINGEN
- Mandates02/07/2018ONTSLAGEN - BENOEMINGEN
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 2024448,9 k €↑
- 2024Name changeMagis Pharma in vereffening
- 2023Annual accounts 2023-146 k €↓
- 2022Annual accounts 2022-139,8 k €↓
- 2021Annual accounts 202176,7 k €↓
- 2021Name changeMagis Pharma
- 2020Annual accounts 2020313,9 k €↑
- 2019Annual accounts 2019-402,2 k €↓
- 2018Annual accounts 2018-73,2 k €↓
- 2017Annual accounts 20171 k €↑
- 2016Annual accounts 2016-119,5 k €↓
- 2015Annual accounts 201534,8 k €↑
- 2014Annual accounts 2014-71,3 k €↑
- 2013Annual accounts 2013-135 k €